Market Cap 6.12B
Revenue (ttm) 0.00
Net Income (ttm) -96.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,347,000
Avg Vol 6,722,514
Day's Range N/A - N/A
Shares Out 115.52M
Stochastic %K 85%
Beta -0.37
Analysts Hold
Price Target $53.00

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Fax: 650 275 4254
Address:
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States
judgeyoung2
judgeyoung2 May. 5 at 5:10 PM
$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.
1 · Reply
Floridaorange
Floridaorange May. 4 at 3:45 PM
$RXRX notice the yearly chart looks like every beatdown SaaS stock? That’s because the market is not accurately valuing or categorizing $RXRX. Miscategorized = mispriced. Earnings this Wed could be the shift. $SMMT $TERN $VKTX
1 · Reply
kubota2323
kubota2323 May. 2 at 2:45 AM
$TERN welp
0 · Reply
kingofking719
kingofking719 Apr. 30 at 6:07 PM
$UAMY $BULL $SOUN $TERN @JarvisProtocols we don't care
1 · Reply
KayJ_
KayJ_ Apr. 30 at 6:00 PM
Have you missed the AKAN Squeeze ?! Are you tired of buying late and chasing?? RYOJ is a next ticker with only about 300 watchers on Stocktwits and recent great news. RYOJ is completely under the radar. With its super tiny float, It squeezed500%+ recently ! Starting to SQUEEZE NOW! Loaded heavy and looking for a big profit short term. You do you. $UAMY $BULL $SOUN $TERN megha
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 4:10 PM
$SLS SLS009 Pristine Safety Profile Durable Efficacy, for the most Dire of AML Mutations, worth more than $TERN and $FTSV You will wish you bought more. We All Will.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 3:38 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 1:46 AM
$SLS $MRK $TERN Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. - this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime. - direct link below - worth a listen for those buying in now on the market tankage. . . . - BUY AND HOLD ALL THAT YOU CAN - your future you will thank you. Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) Omer Jamy — O'Neal Comprehensive Cancer Center, University of Alabama-Birmingham Bradley Christensen — Baylor Scott & White Research Institute Sharif Khan — Bon Secours Hematology & Oncology Dragan Cicic — SELLAS Life Sciences Group Tapan Kadia, MD — MD Anderson Cancer Center
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 10:56 PM
$SLS $MRK $TERN Just the Secondary Asset, SLS009 is worth at Least what GILD Paid for FTSV / $4.9B / $27 Per SLS Share - A Guaranteed 600% ROI - Should See 6 or 7 PR's in the Next 6 to7 months, including Final Randomized Pivotal Results and the AML-IMPACT EU PR in Q2.
0 · Reply
romanaround
romanaround Apr. 29 at 10:12 PM
$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings
0 · Reply
Latest News on TERN
Merck completes Terns Pharmaceuticals acquisition

2026-05-05T13:05:59.000Z - 5 days ago

Merck completes Terns Pharmaceuticals acquisition

MRK


Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 5, 2026, 8:45 AM EDT - 5 days ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

MRK


Merck begins tender offer to acquire Terns Pharmaceuticals

2026-04-07T13:50:37.000Z - 4 weeks ago

Merck begins tender offer to acquire Terns Pharmaceuticals

MRK


Terns Pharmaceuticals downgraded to Hold from Buy at Truist

2026-03-30T20:40:46.000Z - 5 weeks ago

Terns Pharmaceuticals downgraded to Hold from Buy at Truist

MRK


Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

Mar 25, 2026, 6:49 AM EDT - 6 weeks ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK


Terns CEO Amy Burroughs talks cancer drug trial win

Dec 15, 2025, 6:31 PM EST - 5 months ago

Terns CEO Amy Burroughs talks cancer drug trial win


Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 11:30 PM EST - 5 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering


Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 5 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN


Terns Announces Proposed Public Offering

Dec 9, 2025, 6:12 AM EST - 5 months ago

Terns Announces Proposed Public Offering


Terns Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 4:30 PM EST - 5 months ago

Terns Pharmaceuticals Transcript: Study Update


Terns Pharmaceuticals Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 8 months ago

Terns Pharmaceuticals Transcript: Study Update


Terns Pharmaceuticals Transcript: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: Study Result


judgeyoung2
judgeyoung2 May. 5 at 5:10 PM
$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.
1 · Reply
Floridaorange
Floridaorange May. 4 at 3:45 PM
$RXRX notice the yearly chart looks like every beatdown SaaS stock? That’s because the market is not accurately valuing or categorizing $RXRX. Miscategorized = mispriced. Earnings this Wed could be the shift. $SMMT $TERN $VKTX
1 · Reply
kubota2323
kubota2323 May. 2 at 2:45 AM
$TERN welp
0 · Reply
kingofking719
kingofking719 Apr. 30 at 6:07 PM
$UAMY $BULL $SOUN $TERN @JarvisProtocols we don't care
1 · Reply
KayJ_
KayJ_ Apr. 30 at 6:00 PM
Have you missed the AKAN Squeeze ?! Are you tired of buying late and chasing?? RYOJ is a next ticker with only about 300 watchers on Stocktwits and recent great news. RYOJ is completely under the radar. With its super tiny float, It squeezed500%+ recently ! Starting to SQUEEZE NOW! Loaded heavy and looking for a big profit short term. You do you. $UAMY $BULL $SOUN $TERN megha
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 4:10 PM
$SLS SLS009 Pristine Safety Profile Durable Efficacy, for the most Dire of AML Mutations, worth more than $TERN and $FTSV You will wish you bought more. We All Will.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 3:38 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 1:46 AM
$SLS $MRK $TERN Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. - this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime. - direct link below - worth a listen for those buying in now on the market tankage. . . . - BUY AND HOLD ALL THAT YOU CAN - your future you will thank you. Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) Omer Jamy — O'Neal Comprehensive Cancer Center, University of Alabama-Birmingham Bradley Christensen — Baylor Scott & White Research Institute Sharif Khan — Bon Secours Hematology & Oncology Dragan Cicic — SELLAS Life Sciences Group Tapan Kadia, MD — MD Anderson Cancer Center
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 10:56 PM
$SLS $MRK $TERN Just the Secondary Asset, SLS009 is worth at Least what GILD Paid for FTSV / $4.9B / $27 Per SLS Share - A Guaranteed 600% ROI - Should See 6 or 7 PR's in the Next 6 to7 months, including Final Randomized Pivotal Results and the AML-IMPACT EU PR in Q2.
0 · Reply
romanaround
romanaround Apr. 29 at 10:12 PM
$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings
0 · Reply
DonCorleone77
DonCorleone77 Apr. 29 at 7:54 PM
$TERN Attached is a Mizuho analyst note regarding TERN issued today.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 7:21 PM
$SLS $GILD 20% of all AML Patients are AML-MR SLS009 Phase 2B Results in End Stage AML-MR Confirm SLS009 is RIGHT NOW worth More Than the $4.9B GILD Paid for FTSV - and the $7B $MRK paid for $TERN Just the Secondary Asset Guarantees SLS Investors at LEAST a 600% ROI - and a 5,000% + FREE ROLL when GPs Phase 3 Results are Announced. Could be any day.
0 · Reply
TwongStocks
TwongStocks Apr. 28 at 6:15 PM
$TERN Equity Corporate Actions Alert #2026 - 286 Information Regarding the Tender Offer of Terns Pharmaceuticals, Inc. (TERN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-286 The tender offer by $MRK to acquire all of the outstanding common stock of $TERN is scheduled to expire one minute after 11:59 p.m. ET, on May 4, 2026, unless extended or terminated. If successful, the subsequent merger is tentatively scheduled to close prior to the market open on May 5, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 4, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 5th) and will be suspended effective May 6, 2026. TERN shareholders will receive $53 for each share held.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 27 at 9:25 PM
$TERN Attached is page 1 of a Oppenheimer analyst report regarding TERN issued yesterday.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 7:07 PM
$TERN Current Stock Price: $52.95 Contracts to trade: $52.5 TERN May 15 2026 Call Entry: $0.40 Exit: $0.71 ROI: 77% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
YouVSYou
YouVSYou Apr. 27 at 2:36 PM
$ALT baby $TERN Looks like she got dropped on her head after a night out
2 · Reply
DARKP00L
DARKP00L Apr. 27 at 12:37 PM
$TERN 08:13 on Apr. 27 2026 Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Apr. 27 at 11:50 AM
$TERN Oppenheimer downgrades Terns Pharmaceuticals to Perform following Merck deal As previously reported, Oppenheimer downgraded Terns Pharmaceuticals to Perform from Outperform and removed the firm's price target of $58 on the stock. Oppenheimer says Merck's (MRK) acquisition of Terns (TERN) for $53/share in cash equating to an equity value of about $6.7B validates its conviction for the potential of TERN-701 to address underserved chronic myeloid leukemia patients. The firm anticipates Terns shares to continue trading on deal dynamics, and now expects the deal to close near-term in Q2 following the recent HSR waiting period expiration.
0 · Reply
Weedkiller420
Weedkiller420 Apr. 26 at 7:41 PM
$TERN top of my RS screen at 99.83 — but this is deal-arb, not a setup. Merck announced acquisition March 25 at ~$52.89/sh, expected close Q2 2026. Stock is pinned: today's range $52.86–$52.92 vs 52wk high $53.19. RS is a relic of the +1,711% 12mo run pre-deal. No edge here — capital better deployed elsewhere until close.
0 · Reply
De12
De12 Apr. 24 at 6:01 PM
$SLS $TERN bought out over $50 For CML! $SLS should go to $100 for AML!!
0 · Reply
HodlMaBeer
HodlMaBeer Apr. 24 at 5:37 PM
$TERN bye ❤️❤️❤️
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Apr. 24 at 2:06 PM
$SLS all three $CAPR $TERN AND $ALMS shook out retail before the rip Paperhands don't deserve the upcoming gains if data is good.
3 · Reply